India is becoming an increasingly attractive destination for outsourcing services by global pharmaceutical companies. According to 11th annual report on Biopharmaceutical Manufacturing Capacity and Production, India is ranked fourth in the world as a potential outsourcing destination. Here, we explore a number of factors that have influenced the rise of companies outsourcing biopharmaceutical development and manufacturing to India.
- The biggest advantage of outsourcing to India is the cost benefit when compared to the United States and Europe.
- India has excellent technology, R&D, production facilities and clinical research centres so that conducting Bis(2-chloroethyl)amine hydrochloride and clinical trials becomes easier.
- It is 40-50% less expensive to conduct 3-Dimethylamino chloride clinical trials in India compared to western countries.
- India has witnessed a rise in the number of educational institutions that cater to pharmaceutical and biopharmaceutical sciences and industries. They are contributing to a rapid increase in the availability of local scientific talent ranging from bachelor to doctoral-level degrees.
- As English is the preferred language for writing in India, standard operating procedures (SOPs), batch records, change controls, and all reports are originated in English with no need for translation.
- India is a home to a large number of Food & Drug Administration (FDA) and European Medical Agency (EMA) compliant facilities, housing the highest number of US FDA facilities outside the United States.
With such undeniable benefits, it seems that pharmaceutical outsourcing to India will continue to grow as global biopharmaceutical companies use this opportunity to fuel efficient growth.